Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38 MAPK Inhibitor, Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin for Women With Platinum-Sensitive Ovarian Cancer
Conditions
Interventions
LY2228820
Carboplatin
+2 more
Locations
30
United States
St Josephs Hospital and Medical Center
Phoenix, Arizona, United States
Arizona Oncology Associates, P.C.
Tucson, Arizona, United States
Sarasota Memorial Hospital
Sarasota, Florida, United States
H Lee Moffitt Cancer Center
Tampa, Florida, United States
Franklin Square Hospital Center
Baltimore, Maryland, United States
Barnes Jewish Hospital
St Louis, Missouri, United States
Start Date
July 1, 2012
Primary Completion Date
May 25, 2017
Completion Date
May 11, 2018
Last Updated
September 11, 2019
NCT06710548
NCT06915025
NCT02637934
NCT05080946
NCT05281471
NCT04657068
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions